Top

Published in:

01-02-2008 | Original Paper

Hyperhomocysteinemia and central retinal vein occlusion in Iranian population

Authors: Sasan Moghimi, Zahra Najmi, Hooshang Faghihi, Reza Karkhaneh, Mohammad Sadegh Farahvash, Maryam Maghsoudipour

Published in: International Ophthalmology | Issue 1/2008

Abstract

Purpose To evaluate total plasma homocysteine level during the acute phase of central retinal vein occlusion (CRVO) in the Iranian population and determine whether hyperhomocysteinemia is also a risk factor for CRVO. Methods Fifty-four patients with recently diagnosed CRVO were studied. Their fasting total plasma homocysteine level was compared with a matched control group of 51 patients evaluated in the same clinic for a non-retinal disease diagnosis. Results The mean total plasma homocysteine level was 14.76 ± 7.67 μmol/l in cases, and 11.42 ± 3.74 μmol/l in control subjects. It showed a significant difference (P = 0.005) in mean plasma homocysteine level between cases and control group. Odds ratio of CRVO for individuals with hyperhomocysteinemia was 2.88 (95% CI = 1.08−7.71 and P = 0.03). The overall multivariable-adjusted odds of CRVO in participants with plasma homocysteine level above 15 μmol/l was 4.71 (95% CI = 1.46−15.19 and P = 0.009) Hyperhomocysteinemia was not statistically different in each age group (< 60 years: 27%, 61−70 years: 33.3%, 71−80 years: 31.6%, > 81 years: 33.3%, Chi-square test, P = 0.98). Conclusion Elevated total plasma homocysteine level is an independent risk factor for CRVO in Iranian population. In addition to an evaluation of all conventional cardiovascular risk factors, measurement of total homocysteine for evidence of hyperhomocysteinemia may be important in the initial investigation and management of patients with CRVO.

Townend J, O’Sullivan J, Wilde JT (1998) Hyperhomocysteinemia and vascular disease. Blood Rev 12:23–34PubMedCrossRef

Guba SC, Fink LM, Fonseca V (1996) Hyperhomocysteinemia: an emerging and important risk factor for thromboembolic and cardiovascular disease. Am J Clin Pathol 105:709–722

Alfthan G, Aro A, Gey KF (1997) Plasma homocysteine and cardiovascular disease mortality. Lancet 349(9043):397PubMedCrossRef

Frosst P, Blom HJ, Milos R et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111–113PubMedCrossRef

Nygård O, Refsum H, Ueland PM et al (1998) Major lifestyle determinants of plasma homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr 67:263–270PubMed

Morgan SL, Baggott JE, Lee JY et al (1998) Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during long-term, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 25:441–446PubMed

Refsum H, Ueland PM, Nygard O et al (1998) Homocysteine and cardiovascular disease. Ann Rev Med 49:31–62PubMedCrossRef

Selhub J, Jacques PF, Wilson PW et al (1993) Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270:2693–2698PubMedCrossRef

Salahuddin MI, Ahmed SI (2005) Homocysteine level in patients with established transmural myocardial infarction. J Coll Physicians Surg Pak 15:520–523PubMed

10.

Ogawa M, Abe S, Saigo M et al (2003) Homocysteine and hemostatic disorder as a risk factor for myocardial infarction at a young age. Thromb Res 109:253–258PubMedCrossRef

11.

Wang H, Fan D, Zhang H et al (2006) Serum level of homocysteine is correlated to carotid artery atherosclerosis in Chinese with ischemic stroke. Neurol Res 28:25–30PubMedCrossRef

12.

Virtanen JK, Voutilainen S, Happonen P et al (2005) Serum homocysteine, folate and risk of stroke: Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study. Eur J Cardiovasc Prev Rehabil 12:369–375PubMedCrossRef

13.

Malinow MR, Nieto FJ, Szklo M et al (1993) Carotid artery intimal-medial wall thickening and plasma homocysteine in asymptomatic adults: the Atherosclerosis Risk in Communities Study. Circulation 87:1107–1113PubMed

14.

Vine AK (2000) Hyperhomocysteinemia: a risk factor for central retinal vein occlusion. Am J Ophthalmol 129:640–644PubMedCrossRef

15.

Chua B, Kifley A, Wong TY et al (2005) Homocysteine and retinal vein occlusion: a population-based study. Am J Ophthalmol 139:181–182PubMedCrossRef

16.

Abu El-Asrar AM, Abdel Gader AG, Al-Amro SA et al (2002) Hyperhomocysteinemia and retinal vascular occlusive disease. Eur J Ophthalmol 12:495–500PubMed

17.

Terrazzi P, Di Micco P, Quaglia I et al (2005) Homocysteine, MTHFR C677T gene polymorphism, folic acid and vitamin B 12 in patients with retinal vein occlusion. Thromb J 3:13PubMedCrossRef

18.

Yildirim C, Yaylali V, Tatlipinar S et al (2004) Hyperhomocysteinemia: a risk factor for retinal vein occlusion. Ophthalmologica 218:102–106PubMedCrossRef

19.

Weger M, Stanger O, Deutschmann H et al (2002) Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 240:286–290PubMedCrossRef

20.

Cahill M, Karabatzaki M, Donoghue C et al (2001) Thermolabile MTHFR genotype and retinal vascular occlusive disease. Br J Ophthalmol 85:88–90PubMedCrossRef

21.

Martin SC, Raiz S, Marr JE et al (2000) Plasma total homocysteine and retinal vascular disease. Eye 14:590–593PubMed

22.

Brown BA, Marx JL, Ward TP et al (2002) Homocysteine: a risk factor for retinal venous occlusive disease. Ophthalmology 109:287–290PubMedCrossRef

23.

Boyd S, Owens D, Gin T et al (2001) Plasma homocysteine,methylene tetrahydrofolate redoctase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol 85:1313–1315PubMedCrossRef

24.

Pianka P, Almog Y, Man O et al (2000) Hyperhomocystinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion and central retinal vein occlusion. Ophthalmology 107:1588–1592PubMedCrossRef

25.

Larsson J, Hultberg B, Hillarp (2000) Hyperhomocysteinemia and the MTHF C677T mutation in central retinal vein occlusion. Acta Ophthalmol Scand 78:340–343PubMedCrossRef

26.

Pinna A, Carru C, Zinellu A (2006) Plasma homocysteine and cysteine levels in retinal vein occlusion. Invest Ophthalmol Vis Sci 47:4067–6071PubMedCrossRef

27.

McGimpsey SJ, Woodside JV, Bamford L et al (2005) Retinal vein occlusion, homocysteine, and methylene tetrahydrofolate reductase genotype. Invest Ophthalmol Vis Sci 46:4712–4716PubMedCrossRef

28.

Di Crecchio L, Parodi MB, Sanguinetti G et al (2004) Hyperhomocysteinemia and the methylenetetrahydrofolate reductase 677C-T mutation in patients under 50 years of age affected by central retinal vein occlusion. Ophthalmology 111:940–945PubMedCrossRef

29.

Golbahar J, Bararpour H (2003) Normal range of total plasma homocysteine concentrations in southern Iran. IJMS 28:139–142

30.

Graham IM, Daly LE, Refsum HM et al (1997) Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277:1775–1781PubMedCrossRef

31.

Green WR, Chan CC, Hutchins GM et al (1981) Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc 79:371–422PubMed

32.

Lattanzio R, Sampietro F, Ramoni A et al (2006) Moderate hyperhomocysteinemia and early-onset central retinal vein occlusion. Retina 26:65–70PubMedCrossRef

33.

Gao W, Wang YS, Zhang P et al (2006) Hyperhomocysteinemia and low plasma folate as risk factors for central retinal vein occlusion: a case-control study in a Chinese population. Graefes Arch Clin Exp Ophthalmol 244:1246–1249PubMedCrossRef

34.

Cugati S, Wang JJ, Knudtson MD et al (2006) Retinal Vein Occlusion and Vascular Mortality Pooled Data Analysis of 2 Population-Based Cohorts. Ophthalmology.;29 [Epub ahead of print]

35.

Tsaloumas MD, Kirwan J, Vinall H et al (2000) Nine year follow-up study of morbidity and mortality in retinal vein occlusion. Eye 14:821–827PubMed

36.

Van der Griend R, Haas FJ, Biesma DH et al (1999) Combination of low-dose folic acid and pyridoxine for treatment of hyperhomocysteinemia in patients with premature arterial disease and their relatives. Atherosclerosis 143:177–183PubMedCrossRef

37.

Kluijtmans LA, Boers GH, Kraus JP et al (1999) The molecular basis of cystathionine beta-synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. Am J Hum Genet 65:59–67PubMedCrossRef

38.

Miller JW (2001) Does lowering plasma homocysteine reduce vascular disease risk? Nutr Rev 59:242–244PubMed

Title: Hyperhomocysteinemia and central retinal vein occlusion in Iranian population
Authors: Sasan Moghimi
Zahra Najmi
Hooshang Faghihi
Reza Karkhaneh
Mohammad Sadegh Farahvash
Maryam Maghsoudipour
Publication date: 01-02-2008
Publisher: Springer Netherlands
Published in: International Ophthalmology / Issue 1/2008
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-007-9103-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hyperhomocysteinemia and central retinal vein occlusion in Iranian population

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

A case of endogenous bacterial endophthalmitis caused by Streptococcus bovis

Prophylactic use of timolol maleate to prevent intraocular pressure elevation after Nd-YAG laser posterior capsulotomy

Diagnosis of limited ophthalmic wegener granulomatosis: distinctive pathologic features with ANCA test confirmation

Epithelial ingrowth following surgery of recurrent pterygium

Periorbital necrotising fasciitis: delay in diagnosis results in loss of lower eyelid

Localized conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma is amenable to local chemotherapy